Failure to maintain remission · Patients with quiescent ulcerative colitis
Azathioprine may leads to lower failure to maintain remission compared with placebo (low certainty).
1 finding from 1 review
Any adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes any adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes withdrawal due to adverse event compared with placebo (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes failure to maintain remission compared with sulfasalazine (very low certainty).
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Azathioprine probably leads to lower clinical remission compared with infliximab (moderate certainty).
1 finding from 1 review
Clinical remission off steroids · Patients with active Crohn's disease
Azathioprine probably leads to lower clinical remission off steroids compared with infliximab (moderate certainty).
1 finding from 1 review
Mucosal healing · Patients with active Crohn's disease
Azathioprine probably leads to lower mucosal healing compared with infliximab (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine changes withdrawals due to adverse events compared with budesonide (very low certainty).
1 finding from 1 review
Serious adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine changes serious adverse events compared with budesonide (very low certainty).
1 finding from 1 review
Maintenance of remission · maintenance of remission in Crohn's disease
Azathioprine may leads to higher maintenance of remission compared with budesonide (low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine (AZA) changes failure to maintain remission compared with cyclosporin of remission (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher clinical remission compared with infliximab (moderate certainty).
1 finding from 1 review
Clinical remission off steroids · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher clinical remission off steroids compared with infliximab (moderate certainty).
1 finding from 1 review
Mucosal healing · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher mucosal healing compared with infliximab (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
Azathioprine + infliximab showed no clear difference in adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Azathioprine + infliximab showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).
1 finding from 1 review